Senti Biosciences Holdings, Inc. (SNTI) stock
SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.09−0.01 (-10.31%)
Close on Nov 18, 2026Market cap $2.71MP/E –Yield –
Senti Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Senti Biosciences's revenue for the twelve months ending Jun 30, 2025 was $0, down 100.0% year over year. For fiscal 2025 it was $22.00K. The highest annual figure on record is $4.29M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.00K | – |
| FY2024 | Dec 31, 2024 | $0 | -100.0% |
| FY2023 | Dec 31, 2023 | $2.56M | -40.2% |
| FY2022 | Dec 31, 2022 | $4.29M | +55.2% |
| FY2021 | Dec 31, 2021 | $2.76M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $17.00K | – |
| Q1 FY2026 | Mar 31, 2026 | $16.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $0 | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $0 | -100.0% |
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $338.00K | -80.9% |
| Q2 FY2023 | Jun 30, 2023 | $937.00K | -31.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.29M | +16.5% |
| Q4 FY2022 | Dec 31, 2022 | $59.00K | -92.6% |
| Q3 FY2022 | Sep 30, 2022 | $1.77M | +60.1% |
| Q2 FY2022 | Jun 30, 2022 | $1.36M | +71.2% |
| Q1 FY2022 | Mar 31, 2022 | $1.10M | – |
| Q4 FY2021 | Dec 31, 2021 | $793.00K | – |
| Q3 FY2021 | Sep 30, 2021 | $1.10M | – |
| Q2 FY2021 | Jun 30, 2021 | $793.00K | – |
See a number that looks wrong?